CLINICAL TRIAL SUMMARY

MDACC Study No:2011-0016 (clinicaltrials.gov NCT No: NCT01369498)
Title:A Phase 2 Study to Evaluate the Efficacy and Safety of GS-6624 in Adult Patients with Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis
Principal Investigator:Srdan Verstovsek
Treatment Agent:AB0024
Study Status:Closed
Study Description:The goal of this clinical research study is to compare the effectiveness and
safety of GS-6624 at different dose levels with ruxolitinib in patients with
myelofibrosis.

GS-6624 is a drug that is designed to bind to certain proteins. This may
prevent or slow the growth of cancer cells.

Ruxolitinib is designed to block a gene mutation that may be important in
cancer cell growth and survival. Ruxolitinib is the standard of care drug.

Hide details for General InformationGeneral Information

Disease Group:Myeloproliferative Diseases
Phase of Study:Phase II
Treatment Agents:AB0024
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Gilead Sciences, Inc.
Return Visit:
Home Care:


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Srdan Verstovsek
Dept:Leukemia
For Clinical Trial Enrollment:713-792-7305
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults